Salarius Pharmaceuticals Announces Board and Executive Changes
Ticker: DCOY · Form: 8-K · Filed: Nov 19, 2025 · CIK: 1615219
Sentiment: neutral
Topics: management-change, board-of-directors, executive-compensation
TL;DR
Salarius Pharma shakes up board & exec pay - big changes coming?
AI Summary
Salarius Pharmaceuticals, Inc. announced on November 18, 2025, changes in its board of directors and executive compensation arrangements. The filing details the departure of certain officers and the election of new directors, alongside updates to compensatory arrangements for key personnel.
Why It Matters
Changes in a company's board and executive compensation can signal shifts in strategy, operational focus, or financial health, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in board composition and executive compensation can indicate internal restructuring or strategic shifts that may carry inherent risks.
Key Numbers
- 001-36812 — SEC File Number (Identifies the company's filing with the SEC.)
- 46-5087339 — IRS Employer Identification Number (Unique identifier for tax purposes.)
Key Players & Entities
- Salarius Pharmaceuticals, Inc. (company) — Registrant
- November 18, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Houston, TX (location) — Principal executive offices
FAQ
Who are the specific officers that have departed from Salarius Pharmaceuticals?
The filing indicates the departure of certain officers but does not name them specifically in the provided excerpt.
Which new directors have been elected to the Salarius Pharmaceuticals board?
The filing mentions the election of directors but does not provide their names in the excerpt.
What are the details of the updated compensatory arrangements for officers?
The filing notes changes to compensatory arrangements but does not specify the details in the provided text.
What is the exact date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is November 18, 2025.
What is the principal executive office address for Salarius Pharmaceuticals?
The principal executive office is located at 2450 Holcombe Blvd. Suite X, Houston, TX 77021.
Filing Stats: 920 words · 4 min read · ~3 pages · Grade level 12.6 · Accepted 2025-11-19 16:05:16
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 SLRX The Nasdaq Capital Market Indi
- $225,000 — Officer's annual base salary will equal $225,000 ("Base Salary") and each will be eligib
Filing Documents
- flks-20251118.htm (8-K) — 33KB
- a101executiveemploymentagr.htm (EX-10.1) — 57KB
- a102executiveemploymentagr.htm (EX-10.2) — 57KB
- a103executiveemploymentagr.htm (EX-10.3) — 57KB
- 0001615219-25-000168.txt ( ) — 360KB
- flks-20251118.xsd (EX-101.SCH) — 2KB
- flks-20251118_lab.xml (EX-101.LAB) — 22KB
- flks-20251118_pre.xml (EX-101.PRE) — 13KB
- flks-20251118_htm.xml (XML) — 3KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Executive Employment Agreement by and between the Company and Frederick E. Pierce. 10.2 Executive Employment Agreement by and between the Company and Barbara Hibner. 10.3 Executive Employment Agreement by and between the Company and Peter Marschel. 104 Cover Page Interactive Data File (embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SALARIUS PHARMACEUTICALS, INC. Date: November 19, 2025 By: /s/ Mark J. Rosenblum Mark J. Rosenblum Executive Vice President & Chief Financial Officer